Skip to main content
    R

    Rani Therapeutics Holdings Inc (RANI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.68
    +0.01 (+1.46%)

    Market Cap: $94.18M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    86%(19/22)
    Avg Surprise
    +14.15%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.05
    Range$-0.05 - $-0.04
    3 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.06+15.1%
    60d ago$-0.05+12.4%
    30d ago$-0.05+6.6%
    7d ago$-0.05+6.6%
    Current$-0.05
    Revenue Consensus
    $1M
    Range$0 - $2M
    4 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.03
    Range$-0.04 - $-0.03
    3 analysts
    Revenue Consensus
    $4M
    Range$695500 - $5M
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.03---
    Sep 26EST
    		-$-0.05---
    Jun 26
    Reported Aug 13
    		$-0.04$-0.05+20.00%Beat+77.8%
    Mar 26
    Reported May 15
    		$-0.04$-0.04+0.00%Beat+81.8%
    Dec 25
    Reported Mar 26
    		$-0.07$-0.05-47.37%Miss+74.1%
    Sep 25
    Reported Nov 6
    		$-0.12$-0.12+0.00%Beat+50.0%
    Jun 25
    Reported Aug 7
    		$-0.18$-0.19+5.26%Beat+30.8%
    Mar 25
    Reported May 13
    		$-0.22$-0.24+8.33%Beat+24.1%
    Dec 24
    Reported Mar 31
    		$-0.27$-0.26-3.85%Miss+0.0%
    Sep 24
    Reported Nov 14
    		$-0.24$-0.29+17.24%Beat+33.3%
    Jun 24
    Reported Aug 6
    		$-0.26$-0.29+10.34%Beat+29.7%
    Mar 24
    Reported May 6
    		$-0.29$-0.23-26.09%Miss+12.1%
    Dec 23
    Reported Mar 20
    		$-0.27$-0.31+12.90%Beat+22.9%
    Sep 23
    Reported Nov 8
    		$-0.36$-0.37+2.70%Beat-9.1%
    Jun 23
    Reported Aug 11
    		$-0.37$-0.42+11.90%Beat-19.4%
    Mar 23
    Reported May 10
    		$-0.33$-0.43+23.26%Beat-13.8%
    Dec 22
    Reported Mar 22
    		$-0.35$-0.35+0.00%Beat+47.8%
    Sep 22
    Reported Nov 10
    		$-0.33$-0.62+46.77%Beat-153.8%
    Jun 22
    Reported Aug 10
    		$-0.31N/A+53.73%Beat-158.3%
    Mar 22
    Reported May 11
    		$-0.29N/A+56.06%Beat-152.2%
    Dec 21
    Reported Mar 29
    		$-0.67$-1.28+47.66%Beat-461.1%
    Sep 21
    Reported Nov 15
    		$-0.13$-0.20+35.00%Beat-13.9%
    Jun 21
    Reported Aug 2
    		$-0.12$-0.18+33.33%Beat-
    Mar 21
    Reported Jun 2
    		$-0.12$-0.12+4.17%Beat-
    Dec 20
    Reported Mar 31
    		$-0.12$0.00N/AMiss-
    Dec 19
    Reported Mar 30
    		$-0.11$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-2.52EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-517.00%
    ROE-172.20%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest Coverage-18.91x
    Current Ratio5.31xQuick Ratio5.31x
    Trading Statistics
    Beta0.71Avg Volume605.64K
    52-Week High$3.8752-Week Low$0.61

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.77
    SMA 20$0.78
    SMA 50$0.81
    SMA 200$0.98
    EMA 10$0.75
    EMA 20$0.77
    EMA 50$0.80
    EMA 200$0.92

    MACD

    Line: -0.03Signal: -0.01Hist: -0.01

    ADX

    ADX: 22.0+DI: 8.8-DI: 27.1

    Aroon & PSAR

    Aroon Up28.0
    Aroon Down100.0
    PSAR$0.84

    Bollinger Bands

    Upper Band$0.87
    Lower Band$0.69
    %B Position2330%(Upper)
    Band Width-0.03

    RSI (14-Day)

    Neutral
    35.0

    Momentum Oscillators

    Stoch %K11.4
    Stoch %D17.8
    Williams %R-85.1
    ROC (10d)-14.5%
    Momentum-0.12
    CCI (20d)-226.3
    MFI (14d)38.5

    Volatility Measures

    ATR (14d)$0.05(7.7%)
    StdDev (20d)0.05
    Hist Vol60.8%(High)

    Volume Flow

    VWAP$0.67
    OBV747.9M
    AD Line-204.0M
    CMF (20d)-0.367

    Volume Metrics

    Avg Vol (20d)560.9K
    Vol Ratio0.8x
    VWMA (20d)$0.77

    Pivot Points

    R3$0.81
    R2$0.78
    R1$0.73
    Pivot Point$0.69
    S1$0.64
    S2$0.61
    S3$0.55

    Advanced Oscillators

    TSI-15.23
    Ultimate Osc29.7
    KST-74.13

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$1.71M$1.71M$1.46M$0$0$172,000$1.03M$0$0$0$2.75M$0
    Cost of Revenue$0$0$186,000$0$0$0$266,000$0$0$0$227,000$0
    Gross Profit$1.71M$1.71M$1.46M$0$0$172,000$1.03M$0$0$0$2.52M$0
    Operating Expenses$10.54M$10.05M$10.00M$7.26M$10.51M$12.19M$15.98M$11.80M$12.52M$14.03M$13.43M$17.86M
    R&D$5.02M$5.16M$4.91M$3.22M$5.50M$6.57M$6.81M$6.17M$6.12M$7.59M$7.61M$11.22M
    SG&A$5.52M$4.89M$5.09M$4.04M$5.00M$5.62M$5.46M$5.63M$6.41M$6.45M$5.83M$6.63M
    Operating Income$-8,828,000$-8,339,000$-8,535,000$-7,257,000$-10,505,000$-12,013,000$-14,957,000$-11,799,000$-12,524,000$-14,034,000$-13,434,000$-17,855,000
    Interest Income$415,000$412,000$383,000$68,000$158,000$218,000$361,000$414,000$439,000$549,000$675,000$839,000
    Interest Expense$8,000$88,000$922,000$725,000$877,000$943,000$1.13M$1.34M$1.28M$1.29M$1.30M$1.32M
    Income Before Tax$-8,421,000$-8,015,000$-9,074,000$-7,914,000$-11,224,000$-12,738,000$-15,722,000$-12,722,000$-13,361,000$-14,779,000$-30,887,000$-18,332,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-8,421,000$-8,015,000$-9,074,000$-7,914,000$-11,224,000$-12,738,000$-15,722,000$-12,722,000$-13,361,000$-14,779,000$-14,055,000$-18,332,000
    EBITDA$-8,943,000$-8,422,000$-8,436,000$-6,976,000$-10,215,000$-11,854,000$-14,940,000$-11,792,000$-12,879,000$-13,690,000$-13,614,000$-18,188,000
    EBIT$-8,828,000$-8,339,000$-8,535,000$-7,257,000$-10,505,000$-12,013,000$-14,957,000$-11,799,000$-12,524,000$-14,034,000$-13,434,000$-17,855,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about RANI

    News

    Rani Therapeutics to Participate in the Chardan Healthcare Conference

    Rani Therapeutics, a clinical-stage biotherapeutics company, announced its management team will participate in a fireside chat at the upcoming Chardan Healthcare Conference on October 20, 2026. The company...

    Yahoo Finance•10/13/26•Neutral

    Analysts Are Bullish on These Healthcare Stocks: Viking Therapeutics (VKTX), Rocket Pharmaceuticals (RCKT)

    Canaccord Genuity analysts have issued bullish ratings for Viking Therapeutics (VKTX) and Rocket Pharmaceuticals (RCKT). Edward Nash maintained a Buy rating on Viking Therapeutics with a $114.00 price target...

    The Globe and Mail•10/8/26•Neutral

    Tax withholding left Rani Therapeutics (RANI) CEO Imran Talat holding 461,808 shares.

    Rani Therapeutics Holdings, Inc. (RANI) CEO Imran Talat had 7,928 Class A Common Stock shares withheld on September 27, 2026...

    Stock Titan•9/30/26•Neutral

    Form 4 Rani Therapeutics Holdings Inc Class A For: 29 September

    This article reports on the filing of Form 4 for Rani Therapeutics Holdings Inc Class A on September 29. The brief notice from Investing.com indicates this is a routine financial disclosure document. The text provides no...

    Investing.com India•9/29/26•Neutral

    Stock-award tax withholding leaves Rani Therapeutics (RANI) CTO with 9,071 shares.

    Rani Therapeutics (RANI) Chief Technical Officer Alireza Javadi had 309 shares of Class A Common Stock withheld to cover tax withholding obligations related to the settlement of restricted stock units. The transaction...

    Stock Titan•9/29/26•Neutral

    RANI Valuation and Fair Value

    P/E
    -2.5x
    P/B
    3.2x
    See GNG's fair value

    RANI Profitability: Margins, ROIC and FCF

    Operating margin
    -517.0%
    Net margin
    0.0%
    ROE
    -172.2%
    FCF margin
    -417.0%

    RANI Competitors

    CompanyTicker
    Milestone Pharmaceuticals IncMIST
    Pmv Pharmaceuticals IncPMVP
    ImmuCell CorporationICCC
    Anixa Biosciences IncANIX
    Coya Therapeutics, Inc. Common StockCOYA
    Insight Molecular Diagnostics Inc.IMDX
    PolyPidPYPD
    OnKure Therapeutics, Inc.OKUR

    Sector: Healthcare

    RANI Analyst Ratings

    Consensus
    Buy
    Analysts
    5
    Strong Buy
    1
    Buy
    4
    Hold
    0
    Sell
    0
    Strong Sell
    0

    RANI Bull Case vs Bear Case

    Bull case

    • RANI grew quarterly revenue 893.0% year over year.
    • 100.0% of RANI's analyst ratings are Buy or Strong Buy.

    RANI Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    -0.0%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.05
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 0 down

    Frequently Asked Questions About RANI

    Does RANI pay dividends?

    Rani Therapeutics Holdings Inc (RANI) does not currently pay a regular dividend.

    What is RANI's market cap?

    Rani Therapeutics Holdings Inc (RANI) has a market capitalization of $94.18M with a current stock price of $0.68.

    Related stocks

    Sector: Healthcare

    All stocks starting with R

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In